Mark E Arnold

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5727325/publications.pdf

Version: 2024-02-01

84	2,594	156536	252626
papers	citations	32 h-index	46 g-index

90	90	90	2293
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bioanalytical methods: Technological platforms and method validation. , 2022, , 169-187.		0
2	Biomarker Assay Validation by Mass Spectrometry. AAPS Journal, 2022, 24, 66.	2.2	6
3	11th GCC Closed Forum: cumulative stability; matrix stability; immunogenicity assays; laboratory manuals; biosimilars; chiral methods; hybrid LBA/LCMS assays; fit-for-purpose validation; China Food and Drug Administration bioanalytical method validation. Bioanalysis, 2018, 10, 433-444.	0.6	11
4	Overcoming interference with the detection of a stable isotopically labeled microtracer in the evaluation of beclabuvir absolute bioavailability using a concomitant microtracer approach. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143, 9-16.	1.4	8
5	2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines â€˜Scientificâ€™? (Part 1 â€“ LCMS: small molecules, peptides and small molecule biomarkers). Bioanalysis, 2017, 9, 1807-1825.	0.6	34
6	Quantitation of a PEGylated protein in monkey serum by UHPLC-HRMS using a surrogate disulfide-containing peptide: A new approach to bioanalysis and inÂvivo stability evaluation of disulfide-rich protein therapeutics. Analytica Chimica Acta, 2016, 916, 42-51.	2.6	11
7	2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 â€“) Tj ETQq1 1 0.784314 rgBT /Ov	0.6	38
8	Bioanalysis of dried saliva spot (DSS) samples using detergent-assisted sample extraction with UHPLC-MS/MS detection. Analytica Chimica Acta, 2016, 934, 170-179.	2.6	22
9	A highly sensitive and selective LCâ€“MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2016, 119, 145-151.	1.4	6
10	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 â€“) Tj ETQq0 0 0 rgBT /Overlock 1	0.6	35
11	Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 409-418.	1.4	56
12	Selective Reaction Monitoring of Negative Electrospray Ionization Acetate Adduct Ions for the Bioanalysis of Dapagliflozin in Clinical Studies. Analytical Chemistry, 2015, 87, 3247-3254.	3.2	26
13	Sensitive and accurate liquid chromatographyâ€“tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 17-23.	1.4	5
14	A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit. Bioanalysis, 2015, 7, 653-659.	0.6	173
15	â€œCenter punchâ€•and â€œwhole spotâ€•bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 988, 66-74.	1.2	38
16	Development and validation of a liquid chromatography tandem mass spectrometry assay for the quantitation of a protein therapeutic in cynomolgus monkey serum. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 988, 81-87.	1.2	11
17	Implementing Dried Blood Spot Sampling for Clinical Pharmacokinetic Determinations: Considerations from the IQ Consortium Microsampling Working Group. AAPS Journal, 2015, 17, 292-300.	2.2	56
18	A UHPLCâ€“MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 991, 85-91.	1.2	7

#	Article	IF	Citations
19	Post-pellet-digestion precipitation and solid phase extraction: A practical and efficient workflow to extract surrogate peptides for ultra-high performance liquid chromatography â€“ tandem mass spectrometry bioanalysis of a therapeutic antibody in the low ng/mL range. Journal of Chromatography A, 2015, 1424, 27-36.	1.8	35
20	Challenges and solutions in the bioanalysis of BMS-986094 and its metabolites including a highly polar, active nucleoside triphosphate in plasma and tissues using LCâ€“MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1000, 29-40.	1.2	7
21	Introduction to the Proposals from the Global Bioanalysis Consortium Harmonization Team. AAPS Journal, 2014, 16, 1159-1161.	2.2	5
22	2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 â€“ hybrid) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	45
23	Feasibility assessment of a novel selective peptide derivatization strategy for sensitivity enhancement for the liquid chromatography/tandem mass spectrometry bioanalysis of protein therapeutics in serum. Rapid Communications in Mass Spectrometry, 2014, 28, 705-712.	0.7	9
24	Bioanalysis of propylparaben and p-hydroxybenzoic acid, and their sulfate conjugates in rat plasma by liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 947-948, 68-74.	1.2	9
25	Development and validation of an LCâ€“MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target. Bioanalysis, 2014, 6, 2371-2383.	0.6	19
26	A validated LCâ€“MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 973, 1-8.	1.2	19
27	Sensitivity-based analytical approaches to support human absolute bioavailability studies. Bioanalysis, 2014, 6, 497-504.	0.6	19
28	Use of a carboxylesterase inhibitor of phenylmethanesulfonyl fluoride to stabilize epothilone D in rat plasma for a validated UHPLCâ€“MS/MS assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 969, 60-68.	1.2	11
29	Selecting the Correct Weighting Factors for Linear and Quadratic Calibration Curves with Least-Squares Regression Algorithm in Bioanalytical LC-MS/MS Assays and Impacts of Using Incorrect Weighting Factors on Curve Stability, Data Quality, and Assay Performance. Analytical Chemistry, 2014, 86, 8959-8966.	3.2	165
30	A Novel and Cost Effective Method of Removing Excess Albumin from Plasma/Serum Samples and Its Impacts on LC-MS/MS Bioanalysis of Therapeutic Proteins. Analytical Chemistry, 2014, 86, 8336-8343.	3.2	66
31	Improved liquidâ€“liquid extraction with inter-well volume replacement dilution workflow and its application to quantify BMS-927711 in rat dried blood spots by UHPLCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2014, 89, 240-250.	1.4	9
32	Application of a stabilizer cocktail of N-ethylmaleimide and phenylmethanesulfonyl fluoride to concurrently stabilize the disulfide and ester containing compounds in a plasma LCâ€“MS/MS assay. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 552-561.	1.4	22
33	Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: Practical considerations in assay development and validation. Journal of Chromatography A, 2013, 1284, 155-162.	1.8	33
34	A rapid, accurate and robust UHPLCâ€“MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2013, 83, 237-248.	1.4	12
35	Systematic investigation of orthogonal SPE sample preparation for the LCâ€“MS/MS bioanalysis of a monoclonal antibody after pellet digestion. Bioanalysis, 2013, 5, 2379-2391.	0.6	32
36	Simultaneous oral therapeutic and intravenous ¹⁴Câ€microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. British Journal of Clinical Pharmacology, 2013, 75, 763-768.	1.1	72

#	Article	IF	Citations
37	A simplified and completely automated workflow for regulated LCâ€“MS/MS bioanalysis using cap-piercing direct sampling and evaporation-free solid phase extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 921-922, 64-74.	1.2	6
38	A rugged and accurate liquid chromatographyâ€“tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 921-922, 81-86.	1.2	16
39	A validated HPLCâ€“MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: Application to a clinical pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 926, 36-41.	1.2	19
40	Fully Validated LC-MS/MS Assay for the Simultaneous Quantitation of Coadministered Therapeutic Antibodies in Cynomolgus Monkey Serum. Analytical Chemistry, 2013, 85, 9859-9867.	3.2	74
41	The synthesis of a carbonâ€14 labeled pegylated Adnectinâ„¢ for placental transfer studies in guinea pigs. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 492-494.	0.5	5
42	Fit-for-purpose bioanalytical cross-validation for LCâ€“MS/MS assays in clinical studies. Bioanalysis, 2013, 5, 83-90.	0.6	16
43	A User-Friendly Robotic Sample Preparation Program for Fully Automated Biological Sample Pipetting and Dilution to Benefit the Regulated Bioanalysis. Journal of the Association for Laboratory Automation, 2012, 17, 211-221.	2.8	20
44	Simple and efficient digestion of a monoclonal antibody in serum using pellet digestion: comparison with traditional digestion methods in LCâ€“MS/MS bioanalysis. Bioanalysis, 2012, 4, 2887-2896.	0.6	39
45	Automated dried blood spots standard and QC sample preparation using a robotic liquid handler. Bioanalysis, 2012, 4, 2795-2804.	0.6	11
46	When opportunity met aspirational goals: accelerator MS, microdosing and absolute bioavailability studies. Bioanalysis, 2012, 4, 1831-1834.	0.6	11
47	What is next for dried blood spots?. Bioanalysis, 2012, 4, 2059-2065.	0.6	27
48	Overcoming bioanalytical challenges in an Onglyza^{Â®} intravenous [¹⁴C]microdose absolute bioavailability study with accelerator MS. Bioanalysis, 2012, 4, 1855-1870.	0.6	20
49	Practical and Efficient Strategy for Evaluating Oral Absolute Bioavailability with an Intravenous Microdose of a Stable Isotopically-Labeled Drug Using a Selected Reaction Monitoring Mass Spectrometry Assay. Analytical Chemistry, 2012, 84, 10031-10037.	3.2	39
50	Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 889-890, 77-86.	1.2	27
51	A sensitive and accurate liquid chromatographyâ€“tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine. Journal of Chromatography A, 2012, 1245, 117-121.	1.8	34
52	Calculation and Mitigation of Isotopic Interferences in Liquid Chromatographyâ€“Mass Spectrometry/Mass Spectrometry Assays and Its Application in Supporting Microdose Absolute Bioavailability Studies. Analytical Chemistry, 2012, 84, 4844-4850.	3.2	35
53	Esterase inhibitors as esterâ€containing drug stabilizers and their hydrolytic products: potential contributors to the matrix effects on bioanalysis by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2012, 26, 1291-1304.	0.7	11
54	A Convenient Strategy for Quantitative Determination of Drug Concentrations in Tissue Homogenates Using a Liquid Chromatography/Tandem Mass Spectrometry Assay for Plasma Samples. Analytical Chemistry, 2011, 83, 6237-6244.	3.2	23

#	Article	IF	Citations
55	Approach To Evaluating Dried Blood Spot Sample Stability during Drying Process and Discovery of a Treated Card To Maintain Analyte Stability by Rapid On-Card pH Modification. Analytical Chemistry, 2011, 83, 9033-9038.	3.2	52
56	Impact of the implementation of a well-designed electronic laboratory notebook on bioanalytical laboratory function. Bioanalysis, 2011, 3, 1501-1511.	0.6	10
57	Strategy and Its Implications of Protein Bioanalysis Utilizing High-Resolution Mass Spectrometric Detection of Intact Protein. Analytical Chemistry, 2011, 83, 8937-8944.	3.2	67
58	Theory-guided efficient strategy to maximize speed and resolution in rapid gradient LCâ€“MS/MS bioanalysis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 1917-1926.	1.2	9
59	A rugged and accurate liquid chromatographyâ€“tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2064-2072.	1.2	14
60	Implications of differences in bioanalytical regulations between Canada, USA and South America. Bioanalysis, 2011, 3, 253-258.	0.6	6
61	Evaluating and defining sample preparation procedures for DBS LCâ€“MS/MS assays. Bioanalysis, 2010, 2, 1405-1414.	0.6	38
62	Development and validation of sensitive and selective LCâ€“MS/MS methods for the determination of BMS-708163, a Î³-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2319-2326.	1.2	27
63	Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, Ixempraâ„¢) in human plasma: Method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degradants. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 525-537.	1.2	19
64	Effect of mobile phase pH, aqueousâ€organic ratio, and buffer concentration on electrospray ionization tandem mass spectrometric fragmentation patterns: implications in liquid chromatography/tandem mass spectrometric bioanalysis. Rapid Communications in Mass Spectrometry, 2010, 24, 3221-3229.	0.7	36
65	Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LCâ€“MS/MS. Bioanalysis, 2010, 2, 733-743.	0.6	43
66	International harmonization of bioanalytical guidance. Bioanalysis, 2010, 2, 685-687.	0.6	25
67	Novel MS solutions inspired by MIST. Bioanalysis, 2010, 2, 1291-1313.	0.6	44
68	Validated LCâ€“MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma. Bioanalysis, 2010, 2, 2001-2009.	0.6	44
69	Identifying, Evaluating, and Controlling Bioanalytical Risks Resulting from Nonuniform Matrix Ion Suppression/Enhancement and Nonlinear Liquid Chromatographyâ^'Mass Spectrometry Assay Response. Analytical Chemistry, 2010, 82, 9671-9677.	3.2	48
70	Building the Global Bioanalysis Consortium â€“ working towards a functional globally acceptable and harmonized guideline on bioanalytical method validation. Bioanalysis, 2010, 2, 1801-1803.	0.6	41
71	A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 1027-1033.	1.4	43
72	Strategy of Accelerated Method Development for High-Throughput Bioanalytical Assays Using Ultra High-Performance Liquid Chromatography Coupled with Mass Spectrometry. Analytical Chemistry, 2009, 81, 9225-9232.	3.2	51

#	Article	IF	Citations
73	Quantitative determination of BMS-378806 in human plasma and urine by high-performance liquid chromatography/tandem mass spectrometry. Journal of Separation Science, 2007, 30, 1267-1275.	1.3	20
74	Liquidâ€“liquid extraction of strongly protein bound BMS-299897 from human plasma and cerebrospinal fluid, followed by high-performance liquid chromatography/tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1728-1736.	1.4	7
75	Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometryâ€”Evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 77-84.	1.2	28
76	Pharmacokinetics of a Newly Identified Active Metabolite of Buspirone After Administration of Buspirone Over Its Therapeutic Dose Range. Journal of Clinical Pharmacology, 2006, 46, 1308-1312.	1.0	21
77	Increased productivity in quantitative bioanalysis using a monolithic column coupled with high-flow direct-injection liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 1709-1714.	0.7	26
78	Development of a glyburide-metformin fixed combination tablet with optimized glyburide particle size. Drug Development Research, 2005, 66, 25-35.	1.4	2
79	A simple 96-well liquidâ€“liquid extraction with a mixture of acetonitrile and methyl t-butyl ether for the determination of a drug in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2004, 34, 369-378.	1.4	22
80	Determination of a neuroprotective agent (S)-(+)-BMS-204352 in human, rat and dog plasma by enantioselective liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 811, 109-117.	1.2	1
81	Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 795, 215-226.	1.2	61
82	Disposition of radiolabeled BMS-204352 in rats and dogs. Biopharmaceutics and Drug Disposition, 2002, 23, 41-46.	1.1	9
83	High performance liquid chromatographic-mass spectrometric assay for the quantitation of BMS-204352 in dog K3EDTA plasma. Biomedical Chromatography, 2002, 16, 175-182.	0.8	2
84	Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs. Pharmaceutical Research, 1991, 08, 370-375.	1.7	8